BEYOND LOCAL: Researchers say that Health Canada and large pharmaceutical companies are too near to convenience

These are meetings where both sides discuss the company’s upcoming request. The Guidance for Industry of Health Canada on the management of drug submissions sets out some of the objectives: To familiarize the review employees of Health Canada with a submission prior to its arrival, identify any significant unresolved issues, identify whether the surveys presented are sufficient, as well as allow Health Canada to redistribute financing where appropriate.
Moreover, if the latest drug is optimized for clinical trials in animals, fewer individuals will be subjected to unknown hazards. They will be less costly if tests are smaller as well as quicker, and that may mean reduced drug prices.
However, there are potential downsides as well.
More drug safety problems
First, protecting public health is the task of Health Canada, not making it less expensive for businesses to run tests. And the two aren’t synonymous necessarily. Less costly studies are typically smaller studies, but fewer patients also mean that spotting rarer side effects is more difficult before drugs reach the market.
It is also cheaper for drug companies to get through the regulatory framework quicker, but quicker reviews mean more safety issues once drugs are sold. We must also remember that in most instances, Health Canada does not need to market fresh medicines. Only about one in ten offers a substantial improvement over what is already available.
A revolving door
Other countries ‘ regulators are recovering more than 90% of their expenses from businesses. Although an issue is not noticeable here in Canada, there is a rotating door between the Food and Drug Administration and the drug sector in the United States. After resigning as FDA commissioner Dr. Scott Gottlieb, his next step was to Pfizer’s board.